KORU Medical Systems Presents Real-World Evidence on FreedomEDGE® Syringe Infusion System at 51st Oncology Nursing Society Congress
KORU Medical Systems,a leading medical technology company specializing in innovative and patient-centered large-volume subcutaneous infusion solutions, announced that it recently presented new real-world research findings at the Oncology Nursing Society (ONS) Congress, held from May 13–17. The company’s latest poster presentation highlighted the benefits of its FreedomEDGE® Syringe Infusion System in improving workflow efficiency, reducing nursing strain, and enhancing patient satisfaction in clinical infusion settings.
Focus of the ONS Poster Presentation
At the ONS Congress, KORU Medical showcased a scientific poster titled “Reducing Ergonomic Strain During Subcutaneous Monoclonal Antibody Administration.” The study examined how the implementation of the FreedomEDGE® infusion system impacts both healthcare provider experience and patient outcomes in real-world infusion clinic environments.
The abstract evaluated multiple dimensions of clinical performance and operational efficiency, including nursing workflow, caregiver experience, and patient-reported outcomes. The study was conducted across four community infusion centers in the United States, offering a practical and diverse clinical environment for evaluating the system’s effectiveness in routine care.
The findings demonstrated that integrating KORU Medical’s infusion technology into subcutaneous drug delivery workflows can provide measurable benefits across efficiency, safety, and satisfaction metrics.
Key Clinical and Operational Findings
One of the most notable outcomes of the study was the system’s ability to achieve 100% successful dose administration across all evaluated cases. Infusion times were consistently aligned with established clinical guidelines, demonstrating that the FreedomEDGE® system supports predictable and reliable drug delivery performance.
In addition to efficiency outcomes, the study highlighted significant improvements in nursing ergonomics and workload. Nurses reported reduced physical strain when using pump-assisted or tubing-needle set-assisted drug administration methods enabled by the FreedomEDGE® system. This reduction in strain is particularly important in infusion clinic environments, where nurses frequently manage multiple patients and repetitive infusion procedures throughout the day.
The study also found strong improvements in overall user experience. Nurses rated their satisfaction with the system at 4.85 out of 5, reflecting a high level of acceptance and usability in clinical practice. Patients also reported exceptionally positive feedback, with a satisfaction score of 4.92 out of 5, indicating that the system not only supports clinical efficiency but also enhances patient comfort and confidence during treatment.
Another important finding was the system’s impact on workflow flexibility. Nurses reported being able to multitask during approximately 80% of pump-assisted infusions, which suggests that the system allows clinicians to manage other essential responsibilities while ensuring continuous and safe drug delivery. This ability to optimize time and resources can be particularly valuable in high-volume infusion centers where staffing efficiency is critical.
Clinical Perspective and Expert Commentary
Commenting on the findings, Brent Rutland, Vice President of Global Medical and Clinical Affairs at KORU Medical Systems, emphasized the importance of real-world evidence in validating the benefits of the company’s technology in routine care environments.
He noted that the results of the multi-site study provide encouraging evidence that KORU Medical’s infusion solutions are capable of meeting the evolving needs of healthcare providers and patients. According to Rutland, the ability to improve both clinical workflows and patient experiences highlights the practical value of the FreedomEDGE® system beyond controlled clinical trials.
He also emphasized the importance of presenting such findings at major medical congresses like the ONS Congress, where healthcare professionals, researchers, and nursing leaders gather to share advancements in oncology care and evidence-based practice. These platforms, he noted, play a key role in fostering collaboration and advancing innovation in patient care delivery.
Overview of the FreedomEDGE® Syringe Infusion System
KORU Medical’s FreedomEDGE® Syringe Infusion System is part of the broader Freedom System platform, designed to enable, simplify, and enhance the delivery of large-volume subcutaneous therapies. The system is engineered to support a wide range of drug requirements, including varying viscosities, flow rates, and delivery volumes ranging from 5 mL to more than 50 mL.
The Freedom System is widely recognized for its adaptability in both home-based and clinical infusion settings. It is designed to support subcutaneous administration of biologic therapies, including monoclonal antibodies and other specialty drugs that require controlled and consistent infusion performance.
The system is composed of several key components, including the Freedom60® and FreedomEDGE® syringe infusion drivers, Precision Flow Rate Tubing™, and High-Flo Subcutaneous Safety Needle Sets™. Together, these components form an integrated platform that supports safe, reliable, and patient-friendly drug administration.
Market Adoption and Real-World Usage
KORU Medical emphasized the long-standing adoption and global reach of its Freedom System platform. The technology has been used in patient care settings for more than 15 years, particularly in home-based self-administration environments where convenience and autonomy are important.
To date, the system has supported over 59,000 patients and facilitated more than 3 million infusions annually, demonstrating significant scale and consistent usage in real-world healthcare settings. The company also reported a 97% adherence rate across supported therapies, along with compatibility for nine on-label subcutaneous drug products.
In addition, the Freedom System is approved for use in more than 30 countries worldwide, reflecting its broad regulatory acceptance and international adoption across diverse healthcare systems.
Role of the ONS Congress in Advancing Oncology Nursing
The Oncology Nursing Society (ONS) Congress is recognized as one of the largest and most influential professional gatherings dedicated to oncology nursing. The annual event brings together nurses, researchers, educators, and healthcare professionals from across the globe to exchange knowledge, share clinical research, and explore innovations that improve cancer care delivery.
The conference features a wide range of educational sessions, keynote presentations, scientific posters, and networking opportunities. These sessions are designed to promote evidence-based practice and enhance the quality of care delivered to oncology patients.
For companies like KORU Medical Systems, the ONS Congress serves as a critical platform to present real-world data, engage with clinical stakeholders, and gather feedback from frontline healthcare providers who use infusion technologies in daily practice.
Company Background: KORU Medical Systems
KORU Medical Systems develops, manufactures, and commercializes advanced subcutaneous infusion solutions designed to improve patient quality of life and streamline healthcare delivery. The company’s technology is centered around its Freedom Syringe Infusion System, which is used for both self-administration at home and administration in ambulatory infusion centers under healthcare supervision.
The Freedom System, first cleared by the U.S. Food and Drug Administration (FDA) in 1994, has evolved into a widely used platform in subcutaneous drug delivery. Its design supports flexibility across multiple therapeutic areas and drug categories, making it suitable for both clinical trials and commercial applications.
Beyond its core infusion products, KORU Medical also operates a Pharma Services and Clinical Trials division. This business segment provides specialized support to biopharmaceutical companies during drug development, including feasibility studies and clinical trial support. The company also offers customization of its infusion systems to meet specific clinical and commercial requirements, particularly for emerging biologic therapies.
The presentation of KORU Medical Systems’ real-world data at the 51st Oncology Nursing Society Congress underscores the growing importance of patient-centered infusion technologies in modern healthcare. The findings from the multi-site study suggest that the FreedomEDGE® Syringe Infusion System can significantly improve efficiency, reduce nursing strain, and enhance both patient and provider satisfaction in infusion clinic environments.
As subcutaneous administration of biologic therapies continues to expand, solutions like the FreedomEDGE® system are positioned to play an increasingly important role in supporting healthcare systems, improving workflow efficiency, and enhancing patient experience across global clinical settings.
About KORU Medical Systems
KORU Medical develops, manufactures, and commercializes innovative and patient-centric subcutaneous infusion solutions that improve quality of life for patients around the world. The Freedom Syringe Infusion System (the “Freedom System”) currently includes the Freedom60® and FreedomEDGE® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and High-Flo Subcutaneous Safety Needle Sets™. The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by the patient and/or delivery in an ambulatory infusion center by a healthcare professional. Through its Pharma Services and Clinical Trials business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories
